HNSAN Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Proprietary IgG‑cleaving TechnologyHansa’s enzyme-based IgG‑cleaving platform is a durable competitive asset: it targets a specific, hard-to-treat biological mechanism in sensitized transplant patients, creating high technical barriers to replication, enabling niche pricing and differentiated clinical value that supports sustained commercial opportunity and pipeline extension.
Robust Phase III/confirmatory Clinical DataConvincing confirmatory results materially strengthen the clinical and regulatory case for imlifidase: superior kidney function and reduced dialysis dependence support conversion to full approvals, long-term clinician confidence, stronger reimbursement discussions, and a clearer path to durable uptake across transplant centers.
Material Upfront From SERB Out‑licensingThe EUR 110m upfront substantially extends runway and reduces near‑term refinancing pressure, enabling continued investment in U.S. launch readiness, regulatory filings and commercial scaling. That durable liquidity cushion lowers solvency risk while the company executes on approvals and market access initiatives.
Bears Say
Sharp Revenue Decline And Large LossesA severe recent revenue contraction and deeply negative margins signal the company lacks commercial scale. Structurally, continued negative profitability undermines ability to self‑fund growth, weakens negotiating leverage with payers and partners, and raises execution risk for commercialization unless product sales grow meaningfully.
Negative Equity And Elevated DebtA negative equity base plus sizable debt materially increases refinancing and solvency risk over the medium term. This constrains strategic optionality, raises cost of capital, and makes the firm vulnerable to adverse revenue or cash flow shocks that could force dilutive financing or operational retrenchment.
Persistent Operating Cash BurnSustained negative operating cash flow indicates dependence on external funding to sustain operations and commercial roll‑out. Even with one‑time upfronts, recurring burn pressures long‑term planning and could delay or scale back commercialization, R&D or regulatory activities if steady, profitable revenue does not materialize.
HNSAN FAQ
What was Hansa Biopharma AB’s price range in the past 12 months?
Currently, no data Available
What is Hansa Biopharma AB’s market cap?
Hansa Biopharma AB’s market cap is $6.37B.
When is Hansa Biopharma AB’s upcoming earnings report date?
Hansa Biopharma AB’s upcoming earnings report date is Nov 05, 2026 which is in 89 days.
How were Hansa Biopharma AB’s earnings last quarter?
Hansa Biopharma AB released its earnings results on Jul 22, 2026. The company reported -$4.596 earnings per share for the quarter, missing the consensus estimate of -$0.605 by -$3.991.
Is Hansa Biopharma AB overvalued?
According to Wall Street analysts Hansa Biopharma AB’s price is currently Undervalued.
Does Hansa Biopharma AB pay dividends?
Hansa Biopharma AB does not currently pay dividends.
What is Hansa Biopharma AB’s EPS estimate?
Hansa Biopharma AB’s EPS estimate is 10.34.
How many shares outstanding does Hansa Biopharma AB have?
Hansa Biopharma AB has 101,763,220 shares outstanding.
What happened to Hansa Biopharma AB’s price movement after its last earnings report?
Hansa Biopharma AB reported an EPS of -$4.596 in its last earnings report, missing expectations of -$0.605. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Hansa Biopharma AB?
Currently, no hedge funds are holding shares in MX:HNSAN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hansa Biopharma AB
Hansa Biopharma AB (publ) is a biopharmaceutical firm dedicated to developing immunomodulatory therapies. Leveraging its unique enzyme technology platform, the company targets treatments that facilitate organ transplants and address rare autoimmune conditions driven by immunoglobulin G (IgG), alongside applications in gene therapy and cancer. Its primary drug candidate, Imlifidase, an enzyme therapy designed to cleave antibodies, is currently undergoing Phase 3 clinical trials for use in patients awaiting sensitized kidney transplants and those with anti-GBM antibody disease. Imlifidase is also in Phase 2 trials for treating antibody-mediated kidney transplant rejection and Guillain Barré syndrome. Further pipeline developments include NiceR (Novel immunoglobulin cleaving enzymes for Repeat dosing) for autoimmune diseases, transplantation, and oncology, as well as EnzE (Enzyme based antibody Enhancement) for cancer immunotherapy. Hansa Biopharma also has a preclinical research partnership with argenx BV, exploring the synergistic potential of their respective IgG-modulating technologies. Established in 2007, the company's headquarters are located in Lund, Sweden.